Premium
THERAPEUTIC HOTLINE: Infliximab for treatment of resistant pyoderma gangrenosum associated with ulcerative colitis and psoriasis. A case report
Author(s) -
Baglieri Francesco,
Scuderi Giovanni
Publication year - 2010
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/j.1529-8019.2010.01357.x
Subject(s) - pyoderma gangrenosum , medicine , infliximab , ulcerative colitis , psoriasis , dermatology , tumor necrosis factor alpha , inflammatory bowel disease , refractory (planetary science) , disease , crohn's disease , adalimumab , monoclonal antibody , monoclonal , immunology , antibody , physics , astrobiology
Pyoderma gangrenosum (PG) is a rare, noninfectious, neutrophilic dermatosis of unknown origin that is associated with systemic diseases in 50% of cases. The authors present a case of a 54‐year‐old man patient with refractory to conventional treatment PG associated with ulcerative colitis and psoriasis, which showed a successful response to treatment with infliximab, a chimeric monoclonal antibody that inhibits tumor necrosis factor alpha (TNF‐α). This case report shows the frequent difficulty in the therapeutic approach of PG, especially if associated with underlying disease, and necessity to apply new agents, such as a novel application of the TNF‐α inhibitors, in relationship to the recent pathogenic knowledge.